Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2025
[The effectiveness of using a centrally acting muscle relaxant in combination with botulinum toxin injections in patients with spasmodic torticollis].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gusev V V, Makarov E A, Lvova O A, Bogomolova A B
Аннотация
OBJECTIVE: To analyze the efficacy of eperison in combination with botulinum toxin injections for the treatment of pain syndrome in patients with spastic torticollis (ST).
MATERIAL AND METHODS: A retrospective study was conducted to evaluate the effectiveness of eperison administration alongside botulinum therapy in 29 patients diagnosed with ST. The study employed a cross-sectional retrospective analysis of medical data. Patients receiving botulinum toxin injections at three-month intervals (a total of 6 cycles), with assessments at 2 months (4-6 cycles after each injection), were administered eperison at a dose of 150 mg/day. The efficacy of the treatments was evaluated using a validated scale: the 85-point TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale), assessed three times-before each botulinum injection (on day 1), at day 14, and and at day 60 later.
RESULTS: For cycles 1-3 (botulinum toxin, without eperisone), the average TWSTRS scale score on the on day 1 of each cycle was 40.72 - 41.66; cycles 4-6 with the addition of Eperisone - 26.6-30.4 points. When comparing the average values of the TWSTRS scale for cycles 1-3 and cycles 4-6 on the «Pain» scale, t-test value was: 15.85 (p=0.000546).
CONCLUSION: The intake of the centrally acting muscle relaxant eperison resulted in a statistically significant improvement in patients with ST by the time of the next injection (paired Student's t-test 2.77-2.92, p=0.05), including improvements in the «Pain» scale, compared to botulinum therapy without eperison in the same patients.
MATERIAL AND METHODS: A retrospective study was conducted to evaluate the effectiveness of eperison administration alongside botulinum therapy in 29 patients diagnosed with ST. The study employed a cross-sectional retrospective analysis of medical data. Patients receiving botulinum toxin injections at three-month intervals (a total of 6 cycles), with assessments at 2 months (4-6 cycles after each injection), were administered eperison at a dose of 150 mg/day. The efficacy of the treatments was evaluated using a validated scale: the 85-point TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale), assessed three times-before each botulinum injection (on day 1), at day 14, and and at day 60 later.
RESULTS: For cycles 1-3 (botulinum toxin, without eperisone), the average TWSTRS scale score on the on day 1 of each cycle was 40.72 - 41.66; cycles 4-6 with the addition of Eperisone - 26.6-30.4 points. When comparing the average values of the TWSTRS scale for cycles 1-3 and cycles 4-6 on the «Pain» scale, t-test value was: 15.85 (p=0.000546).
CONCLUSION: The intake of the centrally acting muscle relaxant eperison resulted in a statistically significant improvement in patients with ST by the time of the next injection (paired Student's t-test 2.77-2.92, p=0.05), including improvements in the «Pain» scale, compared to botulinum therapy without eperison in the same patients.